Hemobrás
Hemobrás is a Brazilian state-owned pharmaceutical company that manufactures hemoderivatives and biotechnological medicines exclusively for the Brazilian public health system (SUS), producing five essential medicines including Albumin, Immunoglobulin, and clotting factors for hemophilia treatment from its Goiana (PE) facilities.
- Company typePrivate
- Founded2005
- HeadquartersBrasilândia, Brazil
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Hemobrás does
Hemobrás (Empresa Brasileira de Hemoderivados e Biotecnologia) is a Brazilian state-owned pharmaceutical company (empresa pública) linked to the Ministry of Health, established to manufacture blood-derived and biotechnological medicines for the Brazilian public health system (SUS). The company operates two manufacturing facilities in Goiana, Pernambuco: a hemoderivatives plant producing medicines from fractionated human plasma, and a biotechnological medicines plant using recombinant DNA technology. Its product portfolio includes Albumina, Imunoglobulina, Fator VIII Plasmático, Fator IX Plasmático, and Fator VIII Recombinante (Hemo-8r), with Hemo-8r being the first product registered under the Hemobrás brand. It also lists Complexo Protrombínico and Fator de von Willebrand in its broader portfolio.
The company generates revenue exclusively through government procurement contracts with the Ministry of Health, supplying five essential medicines to the SUS for treatment of hemophilia, burns, immunological disorders, and blood clotting disorders. Raw material supply is sourced through the Hemorrede Qualificada, a nationwide network of public and private hemotherapy services that Hemobrás manages under Portaria 1.710/2020. Core manufacturing technology is acquired through technology transfer agreements with LFB (France) for hemoderivatives and Takeda (Japan) for recombinant products, rather than through proprietary R&D. In 2022, the company delivered 82,981 bottles across its portfolio.
Hemobrás operates as a government monopoly supplier within a single-customer, single-country framework: its sole customer is the SUS, and its sole market is Brazil. This structure provides structural revenue stability and regulatory protection but eliminates commercial competition, diversified revenue streams, and growth optionality typical of market-driven pharmaceutical companies. Pricing is determined through public procurement processes and is not publicly disclosed. The company has no external private investors, no funding rounds, and no M&A activity; its capital structure is wholly government-funded.
Hemobrás firmographics
Firmographics- Name
- Hemobrás
- Legal name
- Empresa Brasileira de Hemoderivados e Biotecnologia
- Website
- https://hemobras.gov.br
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Hemobrás is a Brazilian state-owned pharmaceutical company that manufactures hemoderivatives and biotechnological medicines exclusively for the Brazilian public health system (SUS), producing five essential medicines including Albumin, Immunoglobulin, and clotting factors for hemophilia treatment from its Goiana (PE) facilities.
- Ownership category
- akta.pro rank
Hemobrás industry classification
Industry- Product category
- Hemoderivative and Biotechnological Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Plasma Fractionation & Purification Manufacturing (HLAIAHAI)
- akta.pro secondary industries
- Plasma-Derived Coagulation Factors (Hemophilia Therapies) (HLAIAHAB), Plasma-Derived & Blood Products Distributors (HLAIAJAJ)
Keywords
Where Hemobrás is headquartered
LocationHeadquarters
- HQ city
- Brasilândia
- HQ country
- Brazil
- HQ region
- Latin America
Offices1 record
Markets served
Hemobrás business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure
Revenue model
- SUS Medicine Supply: Hemobrás supplies five medicines to the Brazilian public health system (SUS): Albumina, Imunoglobulina, Fator VIII Plasmático, Fator IX Plasmático, and Fator VIII Recombinante (Hemo-8r). Revenue is generated through government procurement contracts with the Ministry of Health.
- Plasma Collection and Management: Hemobrás manages the Brazilian plasma supply through the Hemorrede Qualificada, collecting raw material for hemoderivative production from public and private hemotherapy services across the country under Portaria 1.710/2020.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Hemobrás product offering
Product offeringCore offering
Hemobrás is a state-owned pharmaceutical company that researches, develops, and produces hemoderivative and biotechnological medicines for Brazil's public health system (SUS). It manufactures five core medicines (Albumina, Imunoglobulina, Fator VIII Plasmático, Fator IX Plasmático, and Fator VIII Recombinante/Hemo-8r) using plasma fractionation and recombinant DNA technology at its manufacturing complex in Goiana, Pernambuco. The company also manages Brazil's national plasma supply through the Hemorrede Qualificada under Ministry of Health ordinance.
Product overview
Hemobrás operates two manufacturing facilities in Goiana, PE, Brazil: a hemoderivatives factory and a biotechnological medicines factory. The company produces and supplies five medicines to Brazil's Unified Health System (SUS): Albumin, Immunoglobulin, Plasma-derived Factor VIII and Factor IX, and Recombinant Factor VIII (Hemo-8r). Hemoderivatives are produced from human plasma collected via Brazil's qualified hemotherapy network. Recombinant products use DNA recombinant technology through genetic engineering. The company holds technology transfer agreements with French biotech company LFB (for hemoderivatives) and Takeda (for recombinant Hemo-8r).
Differentiator
Problem solved
Functional benefit
Products and services
- Hemo-8r (Fator VIII Recombinante)
Quantifiable outcome
- 82,981 bottles delivered in 2022
Companies that use Hemobrás
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
Hemobrás technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Hemobrás partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- LFB (Laboratoire Français de Biotechnologie)coreLFB is a French biotechnology laboratory and a strategic technology transfer partner for Hemobrás. The partnership involves transfer of technology for the production of hemoderivative medicines including Albumina, Complexo Protrombínico, Fator VIII e IX da coagulação, Fator de von Willebrand, and Imunoglobulina. This is a core partnership enabling domestic production of plasma-derived medicines in Brazil.
- TakedacoreTakeda is a Japanese pharmaceutical company engaged in technology transfer with Hemobrás for the production of recombinant medicines. Currently, there is an ongoing technology transfer process with Takeda for the production of Hemo-8r (Fator VIII recombinante), Hemobrás' first registered product. This partnership enables domestic production of recombinant blood clotting factors.
- Hemorrede Qualificada (Qualified Blood Network)coreThe Hemorrede Qualificada is a network of public and private hemotherapy services across Brazil that supply plasma to Hemobrás for the production of hemoderivative medicines. Under Portaria 1.710/2020, Hemobrás is responsible for managing Brazilian plasma, collecting raw material from services nationwide.
Scale indicators4 records
Recent moves6 records
Expansion highlights4 records
Hemobrás competitors and assessment
Company assessmentBroad incumbents
- Roche (Chugai): Global pharmaceutical company with a major hemophilia franchise (including recombinant Factor VIII via Chugai/Genentech). Comparable in recombinant coagulation factor manufacturing and global hemophilia market presence.
- Grifols: Global leader in plasma-derived therapies and a major supplier of hemoderivatives (immunoglobulin, coagulation factors, albumin). Comparable in plasma fractionation manufacturing and recombinant product portfolio.
- CSL Behring: Global plasma-derived therapies business of CSL Limited, producing coagulation factors, immunoglobulins, and albumin. Highly comparable to Hemobrás's hemoderivatives portfolio and plasma fractionation operations.
- Takeda: Japanese pharmaceutical company and Hemobrás's technology transfer partner for recombinant Factor VIII (Hemo-8r). Comparable in recombinant coagulation factor manufacturing and global hemophilia franchise.
- Sanofi (Hemophilia Franchise): Global pharmaceutical company with a significant hemophilia and rare disease franchise, including recombinant and plasma-derived coagulation factors. Comparable in recombinant Factor VIII and hemophilia therapeutic offerings.
- Octapharma: Swiss-headquartered manufacturer of plasma-derived medicines (coagulation factors, immunoglobulins, albumin). Comparable in core plasma fractionation and hemophilia therapy product lines.
Direct peers
- Kedrion Biopharma: Italy-based plasma-derived therapies manufacturer with a similar national-champion profile (Italian National Blood Center partnership). Directly comparable in plasma fractionation and supply of hemoderivatives to a national health system.
- Bio Products Laboratory (BPL): UK-based plasma fractionator producing coagulation factors, albumin, and immunoglobulins. Comparable in plasma-derived product portfolio and national/regional public health supply role.
- LFB (Laboratoire Français de Biotechnologie): French state-influenced plasma fractionator that is Hemobrás's core technology transfer partner for hemoderivative production (Albumin, Immunoglobulin, coagulation factors). Directly comparable in plasma-derived medicines manufacturing and national public-health mission.
Regional players
- Instituto Butantan: Brazilian state-owned biomedical institute producing vaccines and biopharmaceuticals. Comparable as a Brazilian public-sector biomanufacturer with a national health system mission similar to Hemobrás.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Hemobrás social profiles
Digital presenceHemobrás financial estimates
Financial estimateRevenue estimate
Valuation estimate
Hemobrás leadership team
Management profileNumber of profiles
Hemobrás funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Hemobrás M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Hemobrás
What does Hemobrás do?
Hemobrás is a state-owned pharmaceutical company that researches, develops, and produces hemoderivative and biotechnological medicines for Brazil's public health system (SUS). It manufactures five core medicines (Albumina, Imunoglobulina, Fator VIII Plasmático, Fator IX Plasmático, and Fator VIII Recombinante/Hemo-8r) using plasma fractionation and recombinant DNA technology at its manufacturing complex in Goiana, Pernambuco. The company also manages Brazil's national plasma supply through the Hemorrede Qualificada under Ministry of Health ordinance.
Is Hemobrás a public or private company?
Hemobrás is a private company. It is classified as state government owned and is currently operating.
When was Hemobrás founded?
Hemobrás was founded in 2005. It employs 251 to 500 people.
Where is Hemobrás based?
Hemobrás is headquartered in Brasilândia, Brazil, in the Latin America region.
How does Hemobrás make money?
Two revenue lines are on record. SUS Medicine Supply is the primary driver. The others are plasma Collection and Management.
Who are Hemobrás's main competitors?
Broad incumbents on record are Roche (Chugai), Grifols, CSL Behring, Takeda, Sanofi (Hemophilia Franchise) and Octapharma. Direct peers are Kedrion Biopharma, Bio Products Laboratory (BPL) and LFB (Laboratoire Français de Biotechnologie). Instituto Butantan is listed as a regional player.
Does Hemobrás have an API?
No public API is recorded for Hemobrás.
What industry is Hemobrás in?
Hemobrás's product category is Hemoderivative and Biotechnological Pharmaceuticals. Its primary akta.pro industry code is HLAIAHAI, Plasma Fractionation & Purification Manufacturing, with a secondary code of HLAIAHAB, Plasma-Derived Coagulation Factors (Hemophilia Therapies). Its NAICS code is 325414 and its SIC code is 2836.